Symbol

    loading  Checking for direct PDF access through Ovid

Abstract

BACKGROUND:

Acute leukemia progressed from myelodysplastic syndrome is a refractory disease with poor clinical therapeutic effect, low remission rate and short survival period. Therefore, it is extremely important to explore a new and effective treatment method.

OBJECTIVE:

To investigate the clinical therapeutic effects and complications of decitabine application combined with allogeneic hematopoietic stem cell transplantation in treatment of acute leukemia progressed from myelodysplastic syndrome.

METHODS:

One patient with acute leukemia progressed from myelodysplastic syndrome received two courses of decitabine application combined with allogeneic hematopoietic stem cell transplantation. Clinical curative effects, the side effects of decitabine and the complications of allogeneic hematopoietic stem cell transplantation were investigated.

RESULTS AND CONCLUSION:

The patient achieved complete remission after two courses of decitabine application combined with allogeneic hematopoietic stem cell transplantation with infection and myelosuppresison. The patient lived without disease for 213 days although acute graft-versus-host disease and pulmonary infection occurred after decitabine application combined with allogeneic hematopoietic stem cell transplantation. These findings suggest that decitabine application combined with allogeneic hematopoietic stem cell transplantation is an effective method to treat acute leukemia progressed from myelodysplastic syndrome, and the side effects and complications can be well controlled.

Related Topics

    loading  Loading Related Articles